Oncopeptides AB (publ) (ONCO.ST)

SEK 1.54

(1.18%)

Market Cap (In SEK)

325.34 Million

Revenue (In SEK)

35.22 Million

Net Income (In SEK)

-249.11 Million

Avg. Volume

1.32 Million

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.426-8.298
PE
-
EPS
-
Beta Value
-0.359
ISIN
SE0009414576
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Sofia Heigis M.Sc.
Employee Count
-
Website
https://www.oncopeptides.com/sv
Ipo Date
2017-02-22
Details
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.